By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel largely agrees that LLY, PH, and MSFT, while high-quality companies, are overvalued and carry significant risks that make them poor choices for dividend growth or inflation hedging at current multiples. The main concerns are valuation risk, payer dynamics, competition, and cyclical exposure.
Risk: Valuation risk and payer/reimbursement dynamics, which could erode growth or squeeze margins, leading to multiple compressions and dividend growth stalling.
Opportunity: None identified as a consensus opportunity.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Income investors love Dividend Kings, that select group of stocks that have increased their dividends for 50 or more consecutive years. They love them for their stability, their fiscal management, and their ability to generate free cash flow.
They're great, but if you're looking to keep up with inflation, maybe it makes more sense to find dividend stocks that have kept up their increases at above-inflationary rates. Those with increases of 50% or more over the past five years but with relatively low payout ratios, so they can continue to keep raising their dividends. Yes, their yields are average or below, but they provide dependable dividend growth and share-price growth.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Three stocks come to mind and they're not coming out of the blue. Pharmaceutical giant Eli Lilly (NYSE: LLY), motion control and technologies conglomerate Parker-Hannifin (NYSE: PH), and tech behemoth Microsoft (NASDAQ: MSFT) have generously boosted dividends by 50% or more over the past five years while growing earnings per share (EPS) by 100% or more, while still keeping payout ratios below 27%.
Why I like all three stocks:
The healthcare company's blockbuster is tirzepatide, a GLP-1 drug sold as Mounjaro for type 2 diabetes and Zepbound for obesity. In the first quarter, Lilly's revenue was reported as $19.8 billion, up 56% year over year, and EPS rose by 156% over the same period a year ago to $8.55. Those numbers could rise now that Foundayo, a daily GLP-1 pill, was approved by the Food and Drug Administration (FDA) to treat adults with weight-related medical problems.
The company's pipeline has 42 phase 3 trials and 32 phase 2 trials, including other potential blockbusters in that mix, such as Alzheimer's treatment donanemab and another GLP-1 drug, retatrutide, which, besides its weight-loss efficacy, could treat non-alcoholic steatohepatitis (NASH/MASH) and severe metabolic dysfunction.
Lilly just increased its dividend by 15.3% to $1.73 per quarterly share. It has increased its dividend for 12 consecutive years and by 104% over the past five years. The payout ratio is only 22.4%, and the company predicts 2026 revenue between $82 billion to $85 billion, up 28% at the midpoint, and EPS from $35.50 to $37, an increase of 49.7% at the midpoint.
While many Dividend Kings offer predictable but sluggish low-single-digit raises, Parker-Hannifin stands out with surprisingly aggressive growth. In April, the industrial company increased its dividend by 11% to $2 per share, marking the 70th consecutive year of dividend increases. Its 5-year dividend growth rate sits near 94%.
As a global leader in motion and control technologies, Parker is a quiet backbone of trends such as near-shoring in global supply chains, factory electrification, and clean technology infrastructure. Because its components are mission-critical but account for a tiny fraction of a client's total project cost, the company possesses immense pricing power.
Parker-Hannifin's business portfolio has evolved to provide longer-cycle, high-margin end markets that buffer it against short-term economic downturns. Its Aerospace Systems segment continues to be a big growth segment, as it saw revenue rise 15.5% year over year in the third quarter to $1.8 billion, while overall revenue increased by 11% over the same period a year ago to a record $5.5 billion. Adjusted EPS rose 18% over the same period a year ago to a record $8.17. Cash flow was a record $2.6 billion. That cash flow keeps the payout ratio a relatively low 26.6%.
Everyone thinks of Microsoft as a growth stock, which it is, thanks to its role in the AI revolution. Its partnership with OpenAI and its huge cloud infrastructure enable it to integrate AI capabilities across its software platform. The tech company has a highly resilient Productivity and Business Processes segment that, thanks to Office 365, Windows commercial, and LinkedIn, operates primarily on a subscription model.
However, Microsoft has a strong record of dividend growth, including a 10% bump last September to $0.91 per quarterly share, the 21st consecutive year it has increased its dividend and usually by 10% or more. It can do that because it steadily grows its businesses. In the third quarter, it reported revenue of $82.9 billion, up 18% year over year, and EPS of 4.27, up 23% over the same quarter in 2025.
Other companies are spending massively to scale data centers, which is driving more revenue for the company's Intelligent Cloud (Azure) and other cloud services, which reported year-over-year revenue growth of 40% in the quarter. Because its customers face incredibly high switching costs once embedded in Microsoft's server and software ecosystem, this cloud revenue represents a durable, wide-moat competitive advantage that will power top-line growth for the next decade.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $438,283! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,257,427!
Now, it’s worth noting Stock Advisor’s total average return is 938% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 12, 2026. *
James Halley has positions in Microsoft and Parker-Hannifin. The Motley Fool has positions in and recommends Eli Lilly and Microsoft. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Elevated valuations and unmentioned competitive/regulatory risks undermine the article's claim that these names reliably beat inflation via dividend growth alone."
The article correctly flags LLY, PH, and MSFT for 50%+ five-year dividend growth and sub-27% payout ratios, but glosses over valuation multiples already embedding aggressive EPS forecasts. LLY trades at 40x+ forward earnings on GLP-1 momentum that faces compounding competition and potential reimbursement caps; PH's industrial exposure remains cycle-sensitive despite its moat claims; MSFT's AI-driven capex surge could pressure free cash flow available for 10%+ annual hikes if Azure growth decelerates. Low yields also limit inflation protection unless share prices keep rising.
If GLP-1 adoption and Azure demand both exceed 2026 guidance, the payout ratios stay low enough for sustained double-digit dividend growth that outpaces inflation regardless of starting valuations.
"Sustained inflation-beating returns from LLY, PH, and MSFT require ongoing GLP-1 adoption, durable global capex demand, and persistent AI/cloud monetization; a miss in any could derail the thesis."
While the article casts Lilly, Parker-Hannifin and Microsoft as inflation-beating dividend-growth plays, the thesis rests on fragile assumptions. Lilly’s gains rely on GLP-1 momentum and a robust drug pipeline, but payer dynamics, pricing pressure, and competition could erode growth or squeeze margins. Parker-Hannifin benefits from long-cycle, high-margin end markets, yet is highly exposed to global capex cycles and aerospace demand; a downturn could stress cash flow and limit further dividend raises. Microsoft’s charm is broad cloud-dominance and AI spend, but a sharp re-rating or slower AI-driven revenue growth could curb dividend capacity. Valuations are rich for the growth baked in.
Strongest counter: even with rising dividends, a waning GLP-1 tailwind, regulatory hurdles for Lilly, cyclicality for Parker-Hannifin, and potential AI slowdown could erode total returns; your income pillar may not be as robust as advertised in a downturn.
"The article ignores that these stocks are priced for perfection, meaning their dividend growth is a secondary factor compared to the massive valuation risk inherent in their current high forward P/E ratios."
This article conflates 'dividend growth' with 'total return' in a way that ignores valuation risk. While LLY, PH, and MSFT are high-quality compounders, buying them specifically for dividend yield or growth at current multiples is a trap. LLY trades at a massive premium based on GLP-1 hyper-growth expectations; any regulatory pricing pressure or supply chain bottleneck could trigger a sharp multiple compression. MSFT is effectively a bond proxy with a tech growth kicker, but its dividend yield is negligible relative to the risk of AI CAPEX overspending. PH is the most sensible play here, but its cyclical exposure to industrial demand makes it a poor hedge against the very inflation the article claims to combat.
If you are a long-term compounder, focusing on the payout ratio and earnings growth is superior to yield-chasing, as these companies consistently reinvest capital at higher returns on invested capital (ROIC) than the average dividend stock.
"LLY's dividend growth story is real, but the stock's 50+ forward P/E already embeds the bull case, leaving limited margin of safety if GLP-1 competition intensifies or obesity-drug adoption plateaus."
The article conflates dividend growth with investment merit. Yes, LLY, PH, and MSFT have raised dividends 50%+ over five years—but that's backward-looking. LLY's valuation has already priced in GLP-1 dominance; the 2026 EPS guidance of $35.50–$37 implies the market is already modeling aggressive growth. PH's 94% five-year dividend growth is impressive, but aerospace exposure creates cyclical risk the article downplays. MSFT's 10% annual raises are sustainable, yet the stock trades at 30x forward earnings—dividend yield is ~0.8%, so you're buying growth, not income. The article's framing—'beat inflation'—is misleading when real yields are negative on all three.
If GLP-1 adoption accelerates faster than expected and LLY's pipeline delivers (donanemab, retatrutide), the stock could re-rate higher despite current valuations; similarly, if AI capex cycles extend longer than consensus, MSFT's cloud moat justifies premium multiples.
"Reimbursement caps on GLP-1 could compress LLY's payout buffer faster than isolated cycle risks imply for the group."
Claude correctly flags LLY's 2026 EPS guidance but misses how that same aggressive modeling already embeds reimbursement and competition risks across GLP-1 names; if payers cap coverage sooner than 2025, the payout-ratio buffer all three stocks rely on shrinks faster than PH's cycle exposure alone would suggest. This creates correlated downside not captured by treating each name's risks in isolation.
"Payer dynamics and macro shocks could erode 2026 dividend-growth assumptions much faster than current valuations imply."
Grok's focus on GLP-1 momentum and AI capex is solid, but you underestimate payer/reimbursement risk intensifying if GLP-1 pricing or biosimilar competition accelerates; that could shave EPS and crimp the payout-flex. A synchronized macro shock could force multiple compressions instead of the single-name 'buffer' you imply. If 2026 guidance stalls, the dividend growth plan collapses much faster than anticipated, even with robust ROIC elsewhere.
"The focus on dividend payout ratios ignores that these companies use buybacks as their primary capital return lever, which is far more vulnerable to macro shocks."
Grok and ChatGPT are missing the structural reality of these firms' capital allocation: they are not dividend plays, they are buyback engines. By focusing on payout ratios, you ignore that these companies prioritize share repurchases over dividends to offset dilution and manage EPS. If the macro environment sours, these firms will slash buybacks long before they touch the dividend, protecting the 'dividend growth' narrative while total shareholder yield collapses. The yield is a distraction from the real risk: valuation-sensitive buyback efficiency.
"Buyback prioritization masks that dividend growth stalls when both levers tighten, not when one does."
Gemini nails the buyback blind spot—but overstates it. LLY and MSFT do prioritize repurchases, yet both maintain rising absolute dividend dollars, not just per-share growth. The real trap: if macro deteriorates, companies cut buybacks *and* decelerate dividend raises simultaneously, not sequentially. That dual compression—not just buyback efficiency loss—is what kills the 'inflation hedge' thesis. Payout ratios only buffer if earnings hold.
The panel largely agrees that LLY, PH, and MSFT, while high-quality companies, are overvalued and carry significant risks that make them poor choices for dividend growth or inflation hedging at current multiples. The main concerns are valuation risk, payer dynamics, competition, and cyclical exposure.
None identified as a consensus opportunity.
Valuation risk and payer/reimbursement dynamics, which could erode growth or squeeze margins, leading to multiple compressions and dividend growth stalling.